Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Fineline Cube Aug 6, 2026
Company Deals

AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang

Fineline Cube Aug 6, 2026
Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026
Company Deals

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Fineline Cube Aug 5, 2026
Company Deals

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

Fineline Cube Aug 5, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults

Fineline Cube Aug 6, 2026
Company Drug

Shandong Boan Biotech Submits BLA to Brazil’s ANVISA for Aflibercept Biosimilar BA9101, Expanding Global Ophthalmic Footprint

Fineline Cube Aug 6, 2026
Company Deals

Moderna Partners with Mitsubishi Tanabe for mRNA Vaccine Promotion in Japan

Fineline Cube Jul 9, 2024

Moderna Inc. (NASDAQ: MRNA), a leading mRNA specialist biotechnology company based in the U.S., has...

Company Deals

Eli Lilly & Co. to Acquire Morphic Holding Inc. in a USD 3.2 Billion Deal

Fineline Cube Jul 9, 2024

Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company in the U.S., has announced...

Company Drug

Roche’s Susvimo Implant Cleared for Relaunch in US After Voluntary Recall

Fineline Cube Jul 9, 2024

Roche (SWX: RO), the Swiss pharmaceutical giant, has announced the conclusion of the voluntary recall...

Company Medical Device

Boston Scientific’s FARAPULSE Pulse Field Ablation System Earns NMPA Approval

Fineline Cube Jul 9, 2024

Boston Scientific Corporation (NYSE: BSX), a leading medical device company in the U.S., has announced...

Company Drug

Ascentage Pharma’s Olverembatinib Receives Marketing Approval from Macau SAR for CML Treatment

Fineline Cube Jul 9, 2024

Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced that it has...

Company Deals

Keymed Biosciences Strikes Licensing Deal with Belenos Biosciences for Global BsAb Rights

Fineline Cube Jul 9, 2024

Keymed Biosciences Inc. (HKG: 2162), a biopharmaceutical company based in China, has entered into a...

Company Deals R&D

Quantum Hi-Tech Partners with East China Normal University to Establish Advanced Drug Research Lab

Fineline Cube Jul 9, 2024

Quantum Hi-Tech (China) Biotechnology Co., Ltd, known as ChemPartner (SHE: 300149), has entered into a...

Company Deals

China Isotope & Radiation Corporation to Establish Cancer Treatment Center in Nigeria

Fineline Cube Jul 9, 2024

China Isotope & Radiation Corporation (CIRC; HKG: 1763), a leading provider of medical equipment and...

Company Drug

Shanghai Fosun Pharmaceutical Gets NMPA Green Light for FH-2001 and Serplulimab Combo Clinical Trial

Fineline Cube Jul 9, 2024

Shanghai Fosun Pharmaceutical Group Co., Ltd (SHA: 600196; HKG: 2196), a prominent pharmaceutical company in...

Company Drug

CSPC Pharmaceutical’s SYS6023 Receives FDA Approval for Clinical Study in Advanced Solid Tumors

Fineline Cube Jul 9, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...

Company Drug

Allist Pharmaceuticals Receives NMPA Approval for Phase III Trial of Furmonertinib in EGFR Mutated NSCLC

Fineline Cube Jul 9, 2024

Allist Pharmaceuticals Co., Ltd, a Shanghai-based biopharmaceutical company, has announced that it has received approval...

Policy / Regulatory

China’s State Council Reportedly Approves Plan to Support Full Industry Chain of Innovative Drug Development

Fineline Cube Jul 8, 2024

A State Council executive meeting, chaired by Chinese Premier Li Qiang, reportedly approved an “Implementation...

Company Drug

AusperBio’s AHB-137 Antiviral Candidate on Path to Breakthrough Designation for Chronic Hepatitis B in China

Fineline Cube Jul 8, 2024

AusperBio, a sino-American developer specializing in liver therapies, has announced that its drug candidate AHB-137...

Company Drug

Yantai Dongcheng Pharmaceutical Gets NMPA Approval for ⁹⁹ᵐTc Tetrofosmin Imaging Agent

Fineline Cube Jul 8, 2024

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a pharmaceutical company based in China, has...

Company Drug

Shenzhen Salubris Pharmaceuticals’ Fotagliptin Receives NMPA Approval for Type 2 Diabetes Treatment

Fineline Cube Jul 8, 2024

Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294), a pharmaceutical company based in China, has announced...

Company Drug

Roche’s Alecensa Secures NMPA Approval as Adjuvant Therapy for Early-Stage NSCLC

Fineline Cube Jul 8, 2024

Roche (SWX: RO), the Swiss pharmaceutical giant, has announced that it has received an additional...

Company Drug

Immorna Earns FDA Approval for Phase I/II Clinical Trial of Self-Replicating RNA Cancer Therapy

Fineline Cube Jul 8, 2024

Immorna (Hangzhou) Biotechnology, a biotech company specializing in mRNA-based vaccines and located in Hangzhou, has...

Company Drug

Novo Nordisk’s Esperoct Receives NMPA Approval, First Long-Acting Factor VIII for Hemophilia A in China

Fineline Cube Jul 8, 2024

The National Medical Products Administration (NMPA) has granted approval to Novo Nordisk (NYSE: NVO), a...

Company Deals Medical Device

Xinzeyuan Medical Technology Secures Over RMB 100 Million in Series B Financing

Fineline Cube Jul 8, 2024

Xinzeyuan Medical Technology Co., Ltd, a Hangzhou-based micro invasive medical device supply chain platform, has...

Company Deals Drug

Innovent Biologics and IASO Biotherapeutics Amend Partnership, Focusing on CAR-T Therapy Fucaso

Fineline Cube Jul 8, 2024

Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced a...

Posts pagination

1 … 372 373 374 … 704

Recent updates

  • Gilead Sciences Reports Q2 2026 Revenue of $7.8B, Driven by HIV Franchise and Trodelvy Growth Despite Cell Therapy Decline
  • Astellas Reports Record Q1 FY2026 Revenue of ¥640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook
  • Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults
  • Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China
  • Luye Pharma’s Novel VMAT2 Inhibitor LY03015 Completes US Bridging Trial with Enhanced Safety Profile in Caucasian Subjects
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Gilead Sciences Reports Q2 2026 Revenue of $7.8B, Driven by HIV Franchise and Trodelvy Growth Despite Cell Therapy Decline

Company

Astellas Reports Record Q1 FY2026 Revenue of ¥640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook

Company Drug

Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults

Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.